Your browser doesn't support javascript.
loading
Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with Type 2 diabetes.
Jiang, Guozhi; Luk, Andrea On Yan; Tam, Claudia Ha Ting; Xie, Fangying; Carstensen, Bendix; Lau, Eric Siu Him; Lim, Cadmon King Poo; Lee, Heung Man; Ng, Alex Chi Wai; Ng, Maggie Chor Yin; Ozaki, Risa; Kong, Alice Pik Shan; Chow, Chun Chung; Yang, Xilin; Lan, Hui-Yao; Tsui, Stephen Kwok Wing; Fan, Xiaodan; Szeto, Cheuk Chun; So, Wing Yee; Chan, Juliana Chung Ngor; Ma, Ronald Ching Wan.
Afiliación
  • Jiang G; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; Li Ka Shing Institute of Health Sciences, The Chinese University of
  • Luk AOY; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; Li Ka Shing Institute of Health Sciences, The Chinese University of
  • Tam CHT; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; Li Ka Shing Institute of Health Sciences, The Chinese University of
  • Xie F; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
  • Carstensen B; Steno Diabetes Centre, Copenhagen, Denmark.
  • Lau ESH; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
  • Lim CKP; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; Li Ka Shing Institute of Health Sciences, The Chinese University of
  • Lee HM; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; Li Ka Shing Institute of Health Sciences, The Chinese University of
  • Ng ACW; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
  • Ng MCY; Center for Genomics and Personalized Medicine Research and Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
  • Ozaki R; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
  • Kong APS; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; Li Ka Shing Institute of Health Sciences, The Chinese University of
  • Chow CC; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
  • Yang X; Department of Epidemiology and Biostatistics, School of Public Health, Tianjin Medical University, Tianjin, China.
  • Lan HY; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
  • Tsui SKW; School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
  • Fan X; Department of Statistics, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
  • Szeto CC; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
  • So WY; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; CUHK-SJTU Joint Research Centre in Diabetes Genomics and Precision M
  • Chan JCN; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; Li Ka Shing Institute of Health Sciences, The Chinese University of
  • Ma RCW; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; Li Ka Shing Institute of Health Sciences, The Chinese University of
Kidney Int ; 95(1): 178-187, 2019 01.
Article en En | MEDLINE | ID: mdl-30415941
Diabetes is a major cause of end stage renal disease (ESRD), yet the natural history of diabetic kidney disease is not well understood. We aimed to identify patterns of estimated GFR (eGFR) trajectory and to determine the clinical and genetic factors and their associations of these different patterns with all-cause mortality in patients with type 2 diabetes. Among 6330 patients with baseline eGFR >60 ml/min per 1.73 m2 in the Hong Kong Diabetes Register, a total of 456 patients (7.2%) developed Stage 5 chronic kidney disease or ESRD over a median follow-up of 13 years (incidence rate 5.6 per 1000 person-years). Joint latent class modeling was used to identify different patterns of eGFR trajectory. Four distinct and non-linear trajectories of eGFR were identified: slow decline (84.3% of patients), curvilinear decline (6.5%), progressive decline (6.1%) and accelerated decline (3.1%). Microalbuminuria and retinopathy were associated with accelerated eGFR decline, which was itself associated with all-cause mortality (odds ratio [OR] 6.9; 95% confidence interval [CI]: 5.6-8.4 for comparison with slow eGFR decline). Of 68 candidate genetic loci evaluated, the inclusion of five loci (rs11803049, rs911119, rs1933182, rs11123170, and rs889472) improved the prediction of eGFR trajectories (net reclassification improvement 0.232; 95% CI: 0.057--0.406). Our study highlights substantial heterogeneity in the patterns of eGFR decline among patients with diabetic kidney disease, and identifies associated clinical and genetic factors that may help to identify those who are more likely to experience an accelerated decline in kidney function.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Nefropatías Diabéticas / Retinopatía Diabética / Albuminuria / Fallo Renal Crónico Tipo de estudio: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Kidney Int Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Nefropatías Diabéticas / Retinopatía Diabética / Albuminuria / Fallo Renal Crónico Tipo de estudio: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Kidney Int Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos